TLR7 Gln11Leu Single Nucleotide Polymorphism and Response to Treatment with Imiquimod in Patients with Basal Cell Carcinoma: A Pilot Study

Piaserico, Stefano; Michelotto, Anna; Frigo, Anna Chiara; Alaibac, Mauro

doi:10.2217/pgs.15.132

Cited by 10 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one published study, the relation between a promoter TRL7 gene SNP (rs179008; not investigated in present study) and response to imiquimod (TLR7 agonist) was explored in cutaneous basal cell carcinoma patients. The results demonstrated that patients carrying at least one SNP allele (T allele) are at an increased risk to be resistant to such therapy [32]. Therefore, TLR7 gene may harbor important functional SNPs that not just influence susceptibility to malignancies, but may also influence response to therapies.…”

Section: Discussionmentioning

confidence: 98%

Serum level and single-nucleotide polymorphisms of toll-like receptor-7 among urinary bladder cancer Iraqi patients

Al-Humairi

Al-Musawi

Ad’hiah

2019

Egypt J Med Hum Genet

View full text Add to dashboard Cite

Background: Toll-like receptor 7 (TLR7), a member of TLR family, plays a pivotal role in pathogenesis of different malignancies. Among these is urinary bladder cancer (UBC), which has not been extensively studied. Therefore, it was aimed to determine TLR7 serum level in UBC patients and evaluate its association with some demographic and clinicopathological characteristics. In addition, four TLR7 single-nucleotide polymorphisms (SNPs: rs179018, rs179019, rs179020, and rs179021) were investigated to determine their susceptibility role in UBC and inspect SNP's impact on TLR7 level. Sixty-six UBC Iraqi patients were enrolled in this case-control study. Two control samples were also involved, 40 urinary tract infection (UTI) patients, and 48 healthy control subjects. Results: Male gender, older age, and cigarette-smoking are risk factors for UBC. TLR7 level showed a significant decreased median in UBC patients compared to UTI patients or control (1.4 vs. 8.1 and 9.5 ng/ml, respectively; p < 0.001). The decrease was more pronounced in males, age group ≥ 48 years, cigarette-smokers, alcohol non-consumers, clinical stages I-II, and superficial tumor, as well as patients with family history of cancer and untreated patients. Mitomycin C and Bacillus Calmette-Guérin therapies tended to increase TLR7 level. Among the four investigated SNPs, only rs179019 C allele showed significantly uncorrected increased frequency in UBC males compared to control males (p = 0.038), while among UTI females, C allele frequency maintained a significantly corrected decreased frequency compared to control females (p = 0.005). Some SNPs influenced serum level of TLR7, but a significant impact was recorded for rs179019 in UTI females (p = 0.006). Conclusions: Downregulation of TLR7 is suggested to have a role in etiology and pathogenesis of UBC, especially the male, elderly and smoker patients. Mitomycin C and Bacillus Calmette-Guérin may enhance TLR7 production in the blood of UBC patients. TLR7 SNPs are suggested to influence susceptibility to develop UBC, and their potential in impacting TLR7 serum level is augmented.

show abstract

Section: Discussionmentioning

confidence: 98%

Serum level and single-nucleotide polymorphisms of toll-like receptor-7 among urinary bladder cancer Iraqi patients

Al-Humairi

Al-Musawi

Ad’hiah

2019

Egypt J Med Hum Genet

View full text Add to dashboard Cite

show abstract

“…Recent and upcoming investigations on targeting Hp signaling in tumors should concentrate on strategies addressing and exceeding resistance mechanisms. The design and development of new generation therapeutics should take into account both downstream genetic variants, such as GLI gain-of-function and SUFU loss-of-function mutations, and acquired SMO mutations [ 45 , 46 ]. In a recent proof of concept, we speculated on the association of, itraconazole, arsenic trioxide, all-trans-retinoic acid and nicotinamide combined with conventionalHp inhibitors to carry out the therapeutic response, prevent tumor resistance and diminish the dosage of each drug and associated AE [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

Patidegib in Dermatology: A Current Review

Cosio

Prete

Raimondo

et al. 2021

IJMS

View full text Add to dashboard Cite

Background: Basal cell carcinoma is one of the most common types of non-melanoma skin cancers, which can be locally destructive despite low-rate metastasis. Surgery is the treatment of choice, but it lacks of efficacy on advanced cases. Hedgehog pathway inhibitors are a class of drugs providing a new therapeutic option for patients affected by advanced disease. Besides systemic therapy, such as vismodegib and sonidegib, also topical inhibitors have been developed. Patidegib is able to decrease tumor burden, reducing the adverse effects induced by systemic targeted therapies. Methods: We performed comprehensive research to summarize the use of patidegib in advanced and recurrent aggressive basal cell carcinomas. Only English language human studies were included in the search. Results: Seven trials reported the application of patidegib. Both topical and systemic patidegib demonstrated safety, tolerability, and efficacy in naïve patients with stage II and III basal cell carcinomas, while stage IV disease and not-naïve patients did not show any benefit. Conclusion: Unlike systemic Hedgehog pathway inhibitors, patidegib 2% gel is not associated with systemic adverse effects and allows a better patient management. Considering the multidisciplinary management of neoplasia, in the era of precision medicine, it is mandatory to confide in pharmacogenomics to obtain personalized combined or sequential therapies.

show abstract

“…Based on the TLR3 and 7 polymorphisms and their correlations with human and mouse susceptibility to viral infections, we propose that avian TLR3 and 7 differences may be associated with either resistance or susceptibility to avian infectious diseases (Schott et al, 2007;Lee et al, 2013;Piaserico et al, 2015;He et al, 2017). This study may be helpful to further understand the varied resistance to viral diseases that exist between different avian species.…”

Section: Identification Of Avian Toll-like Receptor 3 and 7 And Analy...mentioning

confidence: 95%

Identification of Avian Toll-Like Receptor 3 and 7 and Analysis of Gene Variation Sites

Ruan

2022

Braz. J. Poult. Sci.

View full text Add to dashboard Cite

Toll-like receptors 3 and 7 (TLR3 and 7) mediate immune responses through the recognition of viral single-stranded RNA and doublestranded RNA and therefore play important roles in host defense. Differences in TLR3 or 7 may affect host resistance to RNA viral infection. To illuminate these differences, the partial coding sequence (CDS) of TLR3 and 7 genes were cloned and amplified from the Phasianus colchicus and Numida meleagris, total 64 avian species of TLR3 and 7 sequences were later analyzed. Based on the results, 315 nonsynonymous mutation sites and 202 synonymous mutation sites were also observed in the avian TLR3, and 227 non-synonymous mutation sites and 174 synonymous mutation sites were observed in the avian TLR7. Among these sites, 44 and 45 sites were observed in functional regions of TLR3 and 7, used common variation of amino acids in most avian species. A number of these different sites appeared to affect the recognition and were also visualized. H59Y,

show abstract

TLR7 Gln11Leu Single Nucleotide Polymorphism and Response to Treatment with Imiquimod in Patients with Basal Cell Carcinoma: A Pilot Study

Abstract: The results of this study show that patients carrying at least one T allele of the TLR7 promoter polymorphism are associated with an increased probability to be resistant to imiquimod therapy.

Cited by 10 publications

References 12 publications

Serum level and single-nucleotide polymorphisms of toll-like receptor-7 among urinary bladder cancer Iraqi patients

Serum level and single-nucleotide polymorphisms of toll-like receptor-7 among urinary bladder cancer Iraqi patients

Patidegib in Dermatology: A Current Review

Identification of Avian Toll-Like Receptor 3 and 7 and Analysis of Gene Variation Sites

Contact Info

Product

Resources

About